A Deeper Look into Emerging Therapies in the Management of Alzheimer’s Disease (AD): What Does Recent Clinical Trial Data Have to Say?

A continuing medical education activity provided by NAMCP and AAMCN

New Frontiers in the Treatment and Management of AD: What Managed Care Needs to
Know about New and Emerging Therapies is a three-part webinar series

This is Part 3 of the series focusing on emerging therapies in alzheimer’s disease

This activity is an archive from the webinar held November 18, 2020

This activity is valid from December 15, 2020 to December 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer's disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.

Upon completion of this activity, participants will be able to:

  • Characterize the clinical and economic burden of Alzheimer’s disease (AD) in terms of incidence and prevalence as well as direct and indirect costs

  • Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers

  • Explore recent clinical trial data on the efficacy, safety and mechanisms of action of new and emerging therapies in the management of AD

  • Analyze the emerging role of anti-beta-amyloid (Aß) monoclonal antibodies in the management of AD for reduction in clinical decline

  • Appraise the clinical benefits of novel therapeutics addressing neuropsychological symptoms and disease modifying agents in the management of AD


Faculty: Richard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital


Dr. Isaacson serves as a consultant for Eli Lilly and Company, Neurotrack, and 23 and Me. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue